STERIS plc News
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
see moreSTERIS plc Market News
4d
Steris Tariff Headwind Meets Institutional Demand
- Steris (STE) recently reported resilient Q3 results while facing tariff-driven margin pressure. Institutional buying and reaffirmed guidance have stabilized the stock despite short-term gross-margin risk tied to elevated tariffs.
18d
Steris Poised by Reprocessing Surge, No News Brief
Steris (STE) saw no company-specific announcements this week; industry data shows a sharp acceleration in medical-device reprocessing demand, which could support long-term revenue upside. Analysts remain cautiously positive, with a near-term price target implying roughly 24% upside.
25d
Steris (STE): Steam Indicator Shortage Tariff Hits
Recent supply allocations for Steris' steam integrating indicators, combined with tariff headwinds and proxy-season scrutiny, create a near-term operational squeeze with durable revenue resilience from ASCs and recurring services.
07 Apr at 14:47
Steris Soars After Beats; EO Risks Still Loom Now!
Steris (STE) jumped after an earnings beat and raised guidance, drawing investor attention despite lingering ethylene oxide (EO) regulatory risks. Technical indicators show the stock traded oversold while valuation metrics sit near five-year lows, creating a risk/reward trade for investors.
24 Mar at 14:53
Steris Oversold Signal: RSI 24 Sparks Rebound Talk
Steris (STE) registered an oversold technical reading last week with an RSI near 24, drawing investor attention amid calm operational news and positive field-service feedback. This piece reviews the concrete developments, what the oversold condition means for STE in the S&P 500, and practical factors investors should weigh now.
17 Mar at 14:44
Steris (STE) Oversold Signal and Obsolescence Alert!!
Steris (STE) saw a sharp technical oversell (RSI ~24) amid broader market pressures, while issuing a service obsolescence notice for select OR integration monitors. These concrete developments — a pronounced technical indicator, a product lifecycle transition, and ongoing restructuring — create near-term operational and valuation implications for investors.
24 Feb at 14:57
Steris Drops; Danaher-Masimo Deal Rattles MedTech!
Steris (STE) underperformed this week amid elevated trading volume and sector activity. While Steris posted no major company-specific announcements, investors reacted to weaker relative performance versus peers and a flurry of MedTech M&A and earnings updates — notably Danaher's agreed acquisition of Masimo and Medtronic's mixed quarter — which are reshaping investor expectations across the S&P 500 healthcare equipment group.